logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2009 or most recent year available — Summary table by country

Country or region% positive aHBc(1)% positive aHBs(1)% positive HBsAg(1)
YearNumber testedYearNumber testedNational samplesSub-National samplesYearNumber testedNational samplesSub-National samplesYearNumber testedNational samplesSub-National samplesSetting/comments (2) (3) (4) (5)References
Belgium2009358:7.1 - 56.12009374:25.0 - 51.82009380:0.0 - 4.2LTS, DTC; serum22 ; 25 ; 99
Bulgaria::::::::2009941:5.8DTC, NSP, LTS, HTC; serum6 ; 7a ; 7b
Czech Republic::::::::::::::::
Denmark 200618637.1:200410137.0:::::ODD, 5 sites; post mortem blood. IDUnk7
Germany 2004801:53.0::::::::DTC, Vacination study; serum; IDUnk24
Ireland :::::::::::0.0DTC, 1 site; serum14
Greece 2009123915.4 -32.75.3 - 40.72009127531.0 -45.120.0- 57.9200919672.3 - 3.00.0 - 16.2DTC, LTS, OHC, PHL, PRI, OTH serum1 ; 2 ; 9 ; 18
France ::::::::::::::::
Italy20095499136.28.0-75.1::::::::DTC, 533 sites; serum; IDUnk. All markers.48a ; 48b
Cyprus::::::::20091150.9:DTC, PRI, serum10
Lithuania2006526:63.92006324:54.92006668:3.3–8.9HTC, LTS, 16 sites ; serum, dried blood spots5
Luxembourg 200549318.4 - 35.9:200550254.9 - 75.3:20052553.9:DTC, NSP, LTS, STI, ANT, OHC, PRI; serum6
Hungary::::::::20099110.70.0 - 0.7DTC, NSP, PRI, 23 sites; dried blodd spots, serum19 ; 20a ; 20b
Malta2009930.0:::::::::DTC; STI, HTC,2 site, serum7
Netherlands200916:31.3200914:57.1200922:0.0DTC, LTS, 4 sites; serum34
Austria200965213.69.1 - 23.3::::::::LTS, DTC, NSP, 45 sites; serum. All markers.2 ; 3 ; 4 ; 5 ; 12
Poland2004–052009184:26.3 - 56.72004382:31.5 - 34.52009186:2.5 - 3.8DTC, LTS, PRI, STR; serum6 ; 12
Portugal2003-07::::::::200961002.0 - 3.4:DTC; serum, dried blood spots; IDUnk §29 ; 30
Slovenia20093555.4:::::::::DTC, 18 sites; serum5
Slovakia200997:21.6::::::::DTC, 1 site; serum12
Finland ::::::::::::::::
Sweden::2009187:38.5::::PRI, serum ; all markers13
United Kingdom20093289:6.5 - 23.7::::::::DTC, NSP, LTS, primary care;dried blood spots, saliva48 ; 51 ; 52 ; 53 ; 55
Croatia2007/0870524.07.5 - 13.3200870615.04.7 - 13.22007/087910.50.0PRI, DTC, NSP, LTS, PHL, HTC; serum1
Norway2009179:36.92009179:35.22009179:0.0NSP, LTS, 10 sites; serum.16


 This summary table gives a global overview of prevalence of HBV markers in IDUs in the EU, 2009 or most recent year available. Data for more than one year are combined if they clearly improve generalisability (e.g. national data, out-of-treatment data). Prevalence in this table should not be compared with previous versions to follow changes over time, as inclusion of sources may vary according to data availability. For time trends see Tables INF-114 and INF-115

 Sample size is mostly equal for the different HBV markers, where this is not the case the smallest sample size is shown.  

 (1) The figures show estimates (or range of estimates) from national and/or sub-national level samples. 

 (2) Saliva tests for hepatitis B antibodies underestimate prevalence. If test sensitivity is known then figures can be adjusted upwards by dividing prevalence by test sensitivity. Figures have not been adjusted. 

 (3) Having health problems is one selection criterion for admission to drug treatment in some countries or cities (Greece, Portugal, Rome), due to long waiting lists or special programmes for infected IDUs, and this may result in upward bias of prevalence. Prevalence from treatment data should therefore be interpreted in combination with non-treatment data. On the other hand, data from Italy and Portugal include non-IDUs and may thus underestimate prevalence in IDUs. Data for Italy and Austria are not prevalence of aHBc but prevalence of 'all HBV markers' as a proxy of aHBc prevalence. 

 (4) § IDUnk = IDU status not known, prevalence in IDUs is likely to be underestimated. 

 (5) ODD = Overdose Deaths; DEM = Drug Emergencies; DTC = Drug Treatment Centres; NSP = Needle Exchanges; LTS = Low-Threshold Services; PHL = Public Health Laboratories; STI = STI Clinics; ANT = Antenatal Clinics; OHC = Other Hospital or Clinics; PRI = Prisons; ARR = Arrests; GPS = General Practitioners; HTC = HIV Testing Centres; STR = Street; OTH = Other. 

 Portugal: aHBc and aHBs: All studies are IDUnk. HBsAg: Two of three studies are IDUnk (N=1520; 2.0% infected and N=3742; 3.4% infected)                                     


 See Tables INF-114 and INF-115 and INF-0.  

 For references see Table INF-0. Bibliographic References-Part A: References for prevalence data       

(see the help page for information about formats etc.)

Page last updated: Monday, 04 July 2011